Comparison
Both are studied for cognitive enhancement and neuroprotection, and both have origins in Soviet or post-Soviet neuroscience. They differ substantially in composition, mechanism, and administration: Semax is a single synthetic ACTH analogue peptide administered intranasally; Cerebrolysin is a complex mixture of brain-derived peptides administered intravenously or intramuscularly. Cerebrolysin has a substantially larger body of clinical trial data.
Semax is approved in Russia and some former Soviet states as a nasal spray pharmaceutical. Cerebrolysin is approved in multiple European and Asian countries as an IV/IM injection for stroke recovery, dementia, and traumatic brain injury. Both are investigational compounds in the US and UK.
| Attribute | Semax | Cerebrolysin |
|---|---|---|
| Composition | Single synthetic heptapeptide (Met-Glu-His-Phe-Pro-Gly-Pro); ACTH 4-10 analogue | Complex mixture of low-molecular-weight peptides (~25%) and amino acids (~75%) derived from porcine brain tissue via enzymatic hydrolysis |
| Mechanism | BDNF/NGF upregulation, serotonin and dopamine modulation, HIF-1α-mediated neuroprotection | Neurotrophic factor mimicry (mimics BDNF, NGF, GDNF activity); neuroplasticity support, anti-apoptotic signalling, synaptic protection |
| Route | Intranasal spray (approved); SubQ injection (investigational) | Intravenous (IV) infusion or intramuscular (IM) injection |
| Administration setting | Self-administered (nasal spray); accessible outside clinical settings | IV infusion typically requires clinical supervision; IM is more accessible |
| Commonly reported doses | 300–600 mcg intranasally, 1–2× daily | 5–30 mL IV (1–2× daily); 2–5 mL IM; often in courses of 10–30 days |
| Clinical trial base | Moderate; published human trials primarily from Russia; approved in Russia/CIS | Extensive; numerous randomised controlled trials in stroke, vascular dementia, TBI, Alzheimer's; approved in 40+ countries |
| Primary research areas | Cognitive enhancement, anxiety reduction, BDNF upregulation, stroke recovery (post-acute) | Stroke recovery (acute and subacute), vascular dementia, Alzheimer's disease, TBI, cerebrovascular disorders |
The compositional difference between Semax and Cerebrolysin is fundamental. Semax is a single, well-defined synthetic peptide of seven amino acids (a modified fragment of ACTH 4-10) whose pharmacological activity can be characterised precisely. Cerebrolysin is a complex mixture derived from porcine brain tissue hydrolysate: approximately 25% low-molecular-weight peptides (each present in small quantities) and 75% free amino acids. The exact composition of Cerebrolysin varies by batch to a degree inherent in biological extracts, and isolating which specific peptides in the mixture contribute to its observed clinical effects remains an active research question.
Administration route is another major practical difference. Semax is available as an intranasal spray and can be self-administered easily, making it accessible for outpatient and research settings. The intranasal route provides direct CNS delivery via the olfactory pathway, bypassing the blood-brain barrier and first-pass metabolism. Cerebrolysin's primary clinical route is intravenous infusion, which typically requires clinical supervision and venous access, limiting its accessibility. Intramuscular Cerebrolysin is more accessible but produces slower and lower peak plasma concentrations.
The clinical evidence base also differs in both size and character. Cerebrolysin has been investigated in dozens of randomised controlled trials across stroke recovery, Alzheimer's disease, vascular dementia, and traumatic brain injury, resulting in regulatory approvals in over 40 countries. This is among the most extensive clinical datasets of any peptide therapeutic. Semax has a meaningful body of published human research from Russian institutions but a smaller overall randomised trial base, and its approvals are limited primarily to Russia and some CIS countries.
Semax is a synthetic analogue of ACTH 4-10, the segment of the adrenocorticotropic hormone responsible for CNS effects independent of adrenal stimulation. Its primary mechanisms of interest include upregulation of BDNF (brain-derived neurotrophic factor) and NGF (nerve growth factor), modulation of serotonin and dopamine neurotransmitter systems, and activation of HIF-1α-dependent neuroprotective pathways, particularly relevant in ischemic conditions. Research has also documented serotonin transporter modulation, which contributes to its anxiolytic profile.
Cerebrolysin's proposed mechanism involves its low-molecular-weight peptide components crossing the blood-brain barrier and mimicking endogenous neurotrophic factors, including BDNF, NGF, GDNF (glial cell line-derived neurotrophic factor), and CNTF (ciliary neurotrophic factor). Research has investigated its potential role in preventing neuronal apoptosis, supporting synaptic plasticity, reducing amyloid precursor protein processing, and improving mitochondrial function in neurons. The neurotrophic factor mimicry hypothesis is supported by in vitro and in vivo data showing Cerebrolysin-treated neurons exhibiting survival-promoting gene expression patterns.
Semax research has investigated its potential role in:
Cerebrolysin research has investigated its potential role in:
Semax, Reported side effects in research and anecdotal accounts are generally mild: nasal irritation or discomfort, headache, and occasional reports of transient agitation or stimulatory effects at higher doses. Its intranasal delivery and moderate dose ranges contribute to a relatively well-tolerated profile in the research community.
Cerebrolysin, Reported side effects in research and anecdotal accounts include injection site reactions (particularly with IM), mild fever (particularly at higher IV doses), headache, dizziness, nausea, and agitation in some patients. Given its approved pharmaceutical status across multiple countries, its safety profile is supported by post-marketing surveillance data in addition to clinical trial adverse event reporting. Allergic reactions are rarely reported but documented in the literature.
Semax and Cerebrolysin are not typically combined in standard clinical protocols, though anecdotal accounts in the nootropic research community describe combining them. Their mechanisms are not directly overlapping: Semax modulates neurotransmitter systems and BDNF via ACTH-analogue pathways, while Cerebrolysin acts through a broader neurotrophic factor-mimicking mechanism. No published research protocol establishes a combined dose, and the combination remains hypothetical from an evidence standpoint. Logistical considerations, including the IV requirement for optimal Cerebrolysin delivery, also limit casual combination.
Research contexts favouring Semax include investigations into BDNF upregulation, serotonin system modulation, cognitive enhancement in healthy individuals, anxiety and stress resilience, or contexts where intranasal self-administration and accessibility outside clinical settings are required. Its clean compositional profile (single known peptide) also makes it preferable for mechanistic research where attribution of effects to a specific compound is important.
Research contexts favouring Cerebrolysin include clinical investigations into stroke recovery, neurodegenerative disease, or traumatic brain injury where the most extensive clinical evidence base is required, or where the neurotrophic factor-mimicry mechanism (involving multiple BDNF/NGF/GDNF-like activities simultaneously) is the research target. Its approved status in many countries provides regulatory-grade safety data that Semax's smaller trial base cannot currently match.
Yes. Cerebrolysin is derived from porcine (pig) brain tissue through a standardised enzymatic hydrolysis process, resulting in a mixture of low-molecular-weight peptides and free amino acids. The manufacturing process is pharmaceutical-grade, and the final product is a standardised injectable solution with consistent protein nitrogen content specifications.
Research has investigated Semax for its potential role in post-stroke cognitive and functional recovery. It is approved in Russia for this indication. Published data supports activity in post-acute stroke neuroplasticity and recovery contexts. However, its evidence base for stroke specifically is smaller and less rigorously adjudicated by Western regulatory standards than Cerebrolysin's stroke dataset.
Semax is more commonly reported in the nootropic research community for healthy cognitive enhancement contexts: its intranasal self-administration, stimulatory character, and serotonin/dopamine modulation are well-suited to cognitive enhancement research in otherwise healthy individuals. Cerebrolysin's IV delivery and clinical dosing protocols are more aligned with therapeutic rather than enhancement research contexts, though anecdotal use in healthy individuals is reported.
This question has been raised in the research literature given the porcine brain origin. The Cerebrolysin manufacturing process uses enzymatic hydrolysis that produces only peptides and amino acids below a molecular weight threshold at which prion proteins remain structurally intact. Published safety analyses from manufacturing oversight programmes and post-marketing surveillance have not identified prion transmission risk from Cerebrolysin. The compound's 40+ country regulatory approval reflects regulatory review of this question.